Evaluation of Belzutifan in Patients with Tumors Associated with Von Hippel-Lindau Disease: A Retrospective Analysis from a Single Center - Summary - MDSpire
Advertisement
Evaluation of Belzutifan in Patients with Tumors Associated with Von Hippel-Lindau Disease: A Retrospective Analysis from a Single Center
To provide experience on off-label belzutifan treatment in patients with advanced VHL-associated tumors where existing therapies posed a risk of compromising organ function or were ineffective, particularly in cases of severe organ dysfunction.
Key Findings:
Belzutifan demonstrated efficacy in managing advanced VHL-associated tumors, suggesting a shift in treatment paradigms.
Patients faced high risks with conventional surgical options due to organ dysfunction, highlighting the need for alternative therapies.
The treatment was classified as a last-line, organ-preserving option, indicating its critical role in patient management.
Interpretation:
Belzutifan may provide a valuable alternative for patients with advanced VHL-associated tumors, particularly when traditional interventions are not viable, underscoring the necessity for further research.
Limitations:
Retrospective nature of the study limits generalizability and introduces potential biases.
Small sample size and lack of formal quality-of-life assessments may affect the robustness of the findings.
Conclusion:
Belzutifan represents a promising off-label treatment option for patients with advanced VHL-associated tumors, warranting further investigation.
This quality improvement project found that using a distress screening tool for head and neck cancer patients who were 2 or more years post-treatment led to an increased number of referrals for psychosocial needs.
One of the most promising developments in advanced-stage Hodgkin lymphoma is the nivolumab-AVD regimen, which combines nivolumab with doxorubicin, vinblastine, and dacarbazine. This article provides practical knowledge for advanced practitioners to effectively manage the most common toxicities associated with nivolumab-AVD.
